AI in bioinformatics involves applying artificial intelligence techniques to analyze and interpret biological data, enhancing research in genomics, proteomics, and systems biology. A notable application in the bioinformatics market is drug discovery, where AI algorithms analyze vast datasets to identify potential drug candidates efficiently. These AI-driven insights predict interactions between compounds and biological targets, optimizing drug design and clinical trials. This accelerates the development of personalized medicine and reduces the time and cost of bringing new medications to market, improving overall pharmaceutical industry efficiency.
Global AI in Bioinformatics Market is valued at USD 2.53 million in 2022 and is expected to reach USD 217.38 million by 2030, registering a CAGR of 42.7% during the forecast period 2023 to 2030.
To know more, visit https://www.databridgemarketresearch.com/ru/reports/global-ai-in-bioinformatics-market
Below are the Top AI in Bioinformatics Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Illumina, Inc.
|
Illumina, Inc. is a leading company in the field of genomics, known for its advanced sequencing and array-based solutions. In the AI bioinformatics market, Illumina leverages AI to enhance genomic data analysis, enabling faster and more accurate interpretation of sequencing results. Their AI-driven tools support applications in personalized medicine, cancer research, and genetic disease studies, solidifying their position as a critical player in bioinformatics.
|
|
Latin America, North America, Europe, and Asia-Pacific
|
In June 2023, Illumina's unveiling of PrimateAI-3D marks a significant advancement in AI by enhancing genetic risk prediction and drug target discovery. This AI algorithm utilizes primate DNA and sophisticated machine learning to accurately predict disease-causing genetic mutations in patients. Published in Science, the research demonstrates PrimateAI-3D's capability to analyze half a million genomes from the U.K. Biobank, highlighting its potential to accelerate personalized medicine and genomic research.
|
|
2.
|
Dassault Systèmes
|
Dassault Systèmes, a global leader in 3D design and engineering software, applies its expertise to bioinformatics through its BIOVIA brand. The company integrates AI into its solutions to model and simulate biological systems, aiding drug discovery and development. By combining AI with its powerful simulation tools, Dassault Systèmes enhances the efficiency of bioinformatics research and development, promoting innovation in life sciences.
|
|
Latin America, North America, Europe, Middle East and Africa, and Asia-Pacific
|
In June 2020, Dassault Systemes announced that the Migal Galilee Research Institute in Israel had used Dassault Systèmes’ BIOVIA applications to accelerate their research and develop a possible vaccine against SARS-CoV-2. By using BIOVIA for its COVID-19 R&D, Migal Galilee Research Institute has guided its laboratory and experiment management processes with a digital approach that speeds up research results. This has helped the company to increase its global presence in the market.
|
|
3.
|
Eurofins Scientific
|
Eurofins Scientific offers laboratory services, including bioinformatics. The company uses AI to streamline the analysis of biological data from genomics, proteomics, and metabolomics studies. Eurofins' AI-enhanced bioinformatics services improve the accuracy and speed of data interpretation, supporting advancements in pharmaceutical research, clinical diagnostics, and environmental testing.
|
|
Europe, Middle East and Africa, Latin America, North America, and Asia-Pacific
|
In 2024, Eurofins Scientific introduced DiscoveryAI SAFIRE, an advanced AI-driven platform designed to enhance drug discovery processes. Leveraging proprietary datasets, artificial intelligence (AI), and machine learning (ML), SAFIRE accelerates various stages of drug development, from initial hit discovery to lead optimization. This innovation exemplifies the integration of AI in bioinformatics, where sophisticated algorithms analyze complex biological data to predict drug interactions and refine molecular structures. Eurofins' platform underscores how AI is transforming bioinformatics by improving efficiency and precision in pharmaceutical research and development.
|
|
4.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific Inc. is a global leader in serving science, providing comprehensive solutions for research, diagnostics, and clinical laboratories. In the bioinformatics market, they employ AI to analyze complex biological data, enhancing the accuracy and efficiency of genomic sequencing, proteomics, and other omics technologies. Their AI-powered platforms facilitate groundbreaking research and accelerate the development of new therapies.
|
|
Europe, North America, and Asia-Pacific
|
In 2023, Thermo Fisher Scientific's acquisition of Olink Holding AB, particularly in proteomics. Olink's next-generation proteomics solutions integrate advanced data analytics and AI algorithms to interpret complex biological data. This acquisition enhances Thermo Fisher's ability to offer comprehensive solutions in genomic and proteomic analysis, leveraging AI to accelerate discoveries in personalized medicine, biomarker identification, and drug development.
|
|
5.
|
QIAGEN
|
QIAGEN specializes in molecular diagnostics and sample preparation technologies. It improves the analysis of genomic and transcriptomic data. QIAGEN's AI-driven tools assist in identifying biomarkers, understanding disease mechanisms, and developing targeted therapies, making significant contributions to precision medicine and personalized healthcare.
|
|
North America, Europe
|
In 2024, QIAGEN launched QIAGEN Biomedical KB-AI, a new generative AI-driven data base designed to propel drug discovery in the pharma and biotech industries.. This platform utilizes artificial intelligence to analyze vast datasets, enabling data scientists to gain insights into disease mechanisms, identify potential drug targets or biomarkers, and explore strategies for drug repurposing. By integrating AI, QIAGEN enhances the efficiency and accuracy of biomedical research, accelerating the discovery and development of new therapies and personalized medicine solutions.
|
Conclusion
The global AI in bioinformatics market is significantly shaped by key players such as Illumina, Dassault Systèmes, Eurofins Scientific, Thermo Fisher Scientific, and QIAGEN. These companies leverage AI to enhance the analysis and interpretation of complex biological data, driving advancements in personalized medicine, drug discovery, and genomic research. By integrating AI into their bioinformatics solutions, they improve the accuracy, speed, and efficiency of data-driven research. This technological synergy accelerates innovation and paves the way for new therapeutic developments, underscoring the pivotal role of AI in transforming bioinformatics.
